– Reports Revenue of $1.3 Million – Posting third consecutive quarter of growth –– Lowest Quarterly Net Loss in the last Decade – Evidencing further progress toward profitability – SAN JOSE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Energous Corporation d/b/a Energous Wireless Power Solutions (Nasdaq: WATT) (the “Company,” “we,” or “our”), a pioneer in scalable, over-the-air (OTA) wireless power networks, today announced financial results for the third quarter ended September 30, 2025, reporting revenue of approximately $1.3 million for the third quarter, representing a 30% increase versus the second quarter of 2025, and a 38% improvement in net loss in the third quarter compared to the same prior year period. The Company also provided an update on recent events and Company highlights. “We are building the...

MALTA, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) — GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2025. Key Third Quarter Financial HighlightsRevenue of $1.688 billion Gross margin of 24.8% and Non-IFRS gross margin(1) of 26.0% Operating margin of 11.6% and Non-IFRS operating margin(1) of 15.4% Net income of $249 million and Non-IFRS net income(1) of $232 million Diluted earnings per share of $0.44 and Non-IFRS diluted earnings per share(1) of $0.41 Non-IFRS adjusted EBITDA(1) of $573 million Ending cash, cash equivalents and marketable securities of $4.2 billion Net cash provided by operating activities of $595 million and Non-IFRS adjusted free cash flow(1) of $451 million“GF delivered a strong third quarter, with revenue, gross margin, operating...

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patients Leadership team bolstered to support next phase of growth and optimization of business operations Conference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should pre-register using the link at the bottom of this press releaseLONDON and GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — Autolus...

AleAnna, Inc. Reports Positive Net Income, EBITDA, EPS and Cash from Operations in Third Quarter 2025 Third Quarter 2025 Results and Recent Company Highlights:AleAnna generated $5.3 million of net income and $6.3 million of EBITDA(1) in the third quarter driven by strong production at the Longanesi field generating $11.2 million of revenue in the quarter AleAnna reported basic and diluted net income per share of class A common stock of $0.08 for the quarter ended September 30, 2025 AleAnna generated $8.9 million of cash from operations during the third quarter and closed the period with a strong cash position of approximately $31.2 million.DALLAS, Nov. 12, 2025 (GLOBE NEWSWIRE) — AleAnna, Inc. (“AleAnna” or “the Company”) (NASDAQ: ANNA) today announced financial and operational results for the third quarter of 2025. AleAnna...

– Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement –  – Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – – Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations – – Conference call today at 8:00 am ET – DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the third quarter ended September 30, 2025, and provided...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026   Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported...

$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory Skin Disease Summit (ISDS) Strengthened leadership team and board with addition of Dr. Kristin Yarema as Chief Executive Officer, Dr. Kurinji Pandiyan as Chief Strategy and Operations Officer, Dr. Renuka Sivendran as Chief Technical Officer, and Joe Slattery as an independent director SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), a clinical-stage biotechnology...

Revenues Increased by 58%, GAAP Operating Income Rose to $7.5 Million, Adjusted EBITDA Grew to $15.6 Million Raising Midpoint of 2025 Revenue and Adjusted EBITDA Guidance PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the third quarter, ended September 30, 2025. Third Quarter 2025 Financial HighlightsRevenues of $117.7 million, compared with $74.6 million in Q3 2024; GAAP operating income of $7.5 million, compared with GAAP operating income of $6.7 million in Q3 2024; Non-GAAP operating income of $12.8 million, compared with $8.3 million in Q3 2024; GAAP net income of $8.1 million, or $0.14 per diluted share, compared with GAAP net income of $6.8 million,...

–   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end –   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders –   Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2025, and provided a business update. “With a continued commitment to advancing OLC, we are poised...

– Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – – Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) – – Entered into obexelimab funding agreement with Royalty Pharma for up to $300.0 million, including $75M upfront, to support clinical development and potential commercial launch – WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical...